Results

1–10 of 27 results for Phase I

Safety, Tolerability, and Properties of Novel C3 Inhibitor BI-C in Patients With Geographic Atrophy
Brian B. Berger, MD
Annual Meeting Talks
2025
A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy The Phase II ALTITUDE Study
Dilsher S. Dhoot, MD
Annual Meeting Talks
2023
Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy Associated with Rhegmatogenous Retinal Detachment: The Phase II FIXER Trial
Ayman Elnahry, MD, PhD
Annual Meeting Talks
2023
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE® Study
Margaret A. Chang, MD, MS
Updates from the Field
2025
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022